Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023


Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its fourth quarter and full year 2022 financial results before the market opens on Thursday, March 30, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, March 30, 2023.

To access the conference call, please register at: https://register.vevent.com/register/BI24e91f91597f4f97a40e32c908ac7be5. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/cmdsh8s3. Following the webcast, a replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: investors.bettertx.com.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The CBT delivered by Better Therapeutics' PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics' clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com


These press releases may also interest you

at 18:00
Lanesborough Real Estate Investment Trust ("LREIT") today provided an update with regards to its plans for future operations following the failure by the holders of its trust units ("Unitholders") to approve a special resolution approving the sale...

at 18:00
Following an extensive search, Kindred Credit Union (Kindred) is pleased to announce Jason Daly as our next chief executive officer. Jason will assume the role on September 1, 2024. As a seasoned financial services executive, Jason has led teams in...

at 17:44
The PenFed Foundation, a national 501(c)3 founded by PenFed Credit Union, and The 9:57 Project, a veteran-educator nonprofit partnership, celebrated Independence Day and our nation's veterans during pre-game festivities before the July 4 Washington...

at 17:18
The following issues have been halted by CIRO Company: Lanesborough Real Estate Investment Trust TSX-Venture Symbol: LRT.UN All Issues: Yes Reason: Pending News Halt Time (ET): 4:59 PM CIRO can make a decision to impose a temporary suspension...

at 17:05
TransAlta will release its second quarter 2024 results before markets open on Thursday, August 1, 2024. A conference call and webcast to discuss the results will be held for investors, analysts, members of the media and other interested parties the...

at 17:05
KP Tissue Inc. which has a limited equity interest in Kruger Products Inc. (the "Company"), is pleased to announce that the 482 unionized employees at its Crabtree plant and Joliette warehouse have ratified a new five-year collective agreement. "We...



News published on and distributed by: